Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies-Reference-Cited by-同舟云学术

Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies

Published:2014-11-08 Issue:1 Volume:75 Page:111-121
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Marostica Eleonora,Sukbuntherng Juthamas,Loury David,de Jong Jan,de Trixhe Xavier Woot,Vermeulen An,De Nicolao Giuseppe,O’Brien Susan,Byrd John C.,Advani Ranjana,McGreivy Jesse,Poggesi Italo

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-014-2617-3.pdf

Reference23 articles.

1. Byrd JC, Fuman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369:32–42

2. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369:507–516

3. Woyach JA, Johnson AJ, Byrd JC (2012) The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 120:1175–1184

4. Wiestner A (2013) Targeting B-cell receptor signaling for anticancer therapy: the Bruton’s tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 31:128–130

5. Herman SEM, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S et al (2011) Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-3276. Blood 117:6287–6296

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the potential of ibrutinib: A comprehensive review on its role in the multifaceted landscape of cancer therapy;Process Biochemistry;2024-08

2. A phase 2, open-label study of ibrutinib plus rituximab in Japanese patients with Waldenstrom’s macroglobulinemia;International Journal of Hematology;2024-04-10

3. Ibrutinib Efficacy, Safety, and Pharmacokinetics in Chinese Patients with Relapsed or Refractory Waldenström’s Macroglobulinemia: A Multicenter, Single-Arm, Phase 4 Study;Advances in Therapy;2023-12-11

4. Posaconazole‐ibrutinib interaction cannot be avoided by staggered dosing: How to optimize ibrutinib dose during posaconazole treatment;British Journal of Clinical Pharmacology;2023-11-13

5. Silencing of FCRLB by shRNA ameliorates MuSK-induced EAMG in mice;Journal of Neuroimmunology;2023-10